Comparative 3D Assessment of Class III Malocclusion Treatments (NCT07179354) | Clinical Trial Compass
CompletedNot Applicable
Comparative 3D Assessment of Class III Malocclusion Treatments
Turkey (Türkiye)55 participantsStarted 2024-02-21
Plain-language summary
This clinical trial compares three different treatment methods used to correct jaw problems in children with Class III malocclusion (a condition where the lower jaw is positioned forward relative to the upper jaw). The treatments include:
Rapid maxillary expansion with face mask (RME/FM),
Mini maxillary protractor (MMP),
Modified splints with elastics and chin cup (SEC III).
The study aims to understand how each treatment affects the bones and soft tissues of the face, such as how much the upper jaw moves forward or the lower jaw moves backward, as well as changes in teeth alignment and facial appearance. Results showed that different treatments work best for different aspects: some are better for moving the upper jaw forward, while others are better for repositioning the lower jaw. This information helps doctors choose the most suitable treatment plan for each patient.
Who can participate
Age range
9 Months – 12 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Individuals who have not completed their growth spurt (9-12 years old)
* Overjet ≤ 0 mm (patients with negative overjet must be De Nevreze positive)
* ANB ≤ 0°, Witts \< 1
* Good oral hygiene and healthy periodontal tissues
* SN-GoGn angle between 26° and 38°
* No congenital or acquired tooth loss (excluding third molars)
* Body mass index (BMI) between 18-26 kg/m²
* No systemic, local, or endocrinological diseases
Exclusion Criteria:
* Presence of any syndrome or developmental deformity
* Previous orthodontic treatment
* Allergy to any metal or acrylic
* Presence of any systemic disease affecting treatment
* SN-GoGn angle \> 38°
* Presence of temporomandibular joint disorders
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Three-dimensional changes in soft tissues
Timeframe: baseline to post-treatment (≈ 9 months)